QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 reshape-lifesciences-q2-eps-006-up-from-108-yoy-sales-197m-miss-221m-estimate

Reshape Lifesciences (NASDAQ:RSLS) reported quarterly losses of $(0.06) per share. This is a 94.44 percent increase over losses...

 maxim-group-downgrades-reshape-lifesciences-to-hold

Maxim Group analyst Anthony Vendetti downgrades Reshape Lifesciences (NASDAQ:RSLS) from Buy to Hold.

 vyome-has-signed-a-merger-agreement-with-reshape-lifesciences-to-go-public-and-trade-on-the-nasdaq-capital-market-under-the-ticker-symbol-hind

Vyome Therapeutics, a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global ma...

 reshape-lifesciences-receives-notice-of-allowance-for-us-patent-application-titled-intragastric-volume-occupying-device-and-method-for-fabricating-same-for-treating-obesity

https://patentcenter.uspto.gov/applications/16865242/ifw/docs

 why-reshape-lifesciences-stock-is-moving-higher-wednesday

ReShape Lifesciences reported that it gained approval from the United States Patent and Trademark Office for its application en...

 amid-ozempics-miracle-weight-loss-craze-this-company-peaked-over-100-in-tuesday-pre-market-after-receiving-us-patent-for-obesity-treatment

The approval comes at a time when global demand for weight loss drugs like Ozempic and WeGovy is increasing.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION